Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs
M. Opdam, N. Den Broeder, Bart J. F. van den Bemt, Kelly Mulder, Kayleigh M van de Wiel, Hanne van Ballegooijen, Reinout van Crevel, Alfons A den Broeder
Topics & Concepts
TofacitinibMedicineInternal medicineRheumatoid arthritisJanus kinase inhibitorRheumatologyIncidence (geometry)OpticsPhysicsRheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and TreatmentsAutoimmune and Inflammatory Disorders Research